Publications
Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.
Sponsored by Boehringer Ingelheim.
June 2025
Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial
Lancet Rheumatol 2025;7:e323–32 doi: org/10.1016/S2665-9913(24)00334-5
Fretheim et al. showed that the faecal microbiota transplantation with ACHIM was well-tolerated in participants with systemic sclerosis but did not result in an improvement in lower GIT symptoms. Fretheim et al. compared the effects of repeated upper intestinal infusions of ACHIM with placebo in patients with systemic sclerosis and moderate-to-severe lower GIT symptoms. The ReSScue trial provides valuable insights that can inform future GIT studies in patients with systemic sclerosis.
A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis
Rheumatology 2025;64:3657–66 doi: org/10.1093/rheumatology/keaf066
Denton et al. showed that SC administration of immunoglobulin is generally well-tolerated in patients with dcSSc. Denton et al. evaluated the safety of IgPro20 in adults with dcSSc by recording of AEs, TEAEs, AE of special interests, ISRs and associated clinical tests. The secondary objectives were assessing PK and relative bioavailability of IgPro20, and the safety profile and PK of IgPro10. The ISR rate was low with no severe or serious TEAEs affecting the skin reported, despite moderate-to-severe skin involvement in all subjects and pathological skin features. Overall safety, PK and bioavailability profiles of IgPro20, and safety and PK of IgPro10 were similar to those observed in other indications.
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Ann Rheum Dis 2025;84:29–40 DOI: 10.1136/ard-2024-226430
Del Galdo et al. formed a new task force to update the EULAR recommendations for the pharmacological management of systemic sclerosis (SSc). The task force agreed on 22 new recommendations covering eight clinical/organ domains: Raynaud’s phenomenon (RP), digital ulcers, pulmonary arterial hypertension (PAH), musculoskeletal, skin fibrosis, interstitial lung disease (ILD), gastrointestinal, and renal crisis.
Keywords:
Comparative efficacy of immunosuppressive therapies in the treatment of diffuse cutaneous systemic sclerosis
ACR Open Rheumatol 2025;7:e70004 DOI: 10.1002/acr2.70004.
White et al. report a post hoc analysis of the RESOLVE-1 trial comparing immunosuppressive therapies in diffuse cutaneous systemic sclerosis (dcSSc), finding numerically greater improvement in modified Rodnan skin score and stabilisation of lung function with mycophenolate mofetil (MMF), particularly in patients with early-stage disease and anti–topoisomerase 1 antibodies. These findings strongly support MMF as a preferred background therapy in this population.